<DOC>
	<DOCNO>NCT02428374</DOCNO>
	<brief_summary>The fascinating role lymphocyte subtypes development coronary artery disease may new strategic target understanding therapy acute myocardial infarction . The determinant cell viability unknown , postulating arise factor related microcirculation energy expenditure , also inflammatory immune response . Furthermore , intense mobilization progenitor cell secondary myocardial infarction trigger large lymphocyte proliferation colonize plaque development , contribute recurrent ischemic outcome . This project aim evaluate immune metabolic mechanism involve recovery ischemic myocardium coronary disease progression .</brief_summary>
	<brief_title>Role Immune Responses After Acute Myocardial Infarction</brief_title>
	<detailed_description>Specifically , investigator study innate adaptive immunity , emphasis lymphocyte subtypes involve early late surrogate outcome patient acute myocardial infarction , characterization ( B1 , B2 T lymphocytes ) cell culture flow-cytometry , immune response ( IgM IgG oxLDL specific epitope apoB ) . In addition , project evaluate new biomarkers identify study metabolomics , well correspond signal pathway . Therapeutic pharmacological strategy change intestinal microbiota evaluate since acute phase myocardial infarction 6 month . In study , investigator compare four arm combine therapy : clopidogrel rosuvastatin ; clopidogrel simvastatin ; ticagrelor rosuvastatin ; ticagrelor simvastatin . The investigator 's hypothesis improvement microcirculation rosuvastatin ticagrelor ( synergic pleiotropic effect ) may decrease infarcted mass area , result well leave ventricular ejection fraction compare combined therapy . The monitoring genotype microbiota examine together metabolomics cardiac MRIs obtain acute phase MI 1-mo 6-mo FU .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>1 . Stable patient ST elevation myocardial infarction ( STEMI ) treat thrombolytic first 6h initial symptom MI . 1 . Contraindication know intolerance study drug protocol 2 . Those comorbidities neoplasm , renal insufficiency ( stage 4 high ) Patients randomize first 24 hour AMI treat one four combined therapy least 2h prior coronary angiogram follow percutaneous intervention necessary .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>MRI</keyword>
	<keyword>Ventricular function , leave</keyword>
</DOC>